

Scket: 01834CIP/HG

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Takeshi IMANISHI et al. Applicant(s):

10/054,300 Serial No. :

Filed January 22, 2002

NOVEL BICYCLONUCLEOSIDE For

ANALOGUES

Art Unit : 1646

Examiner

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Express Mail Mailing Label No.: EV 075 593 470 US Date of Deposit: April 19, 2002 I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service with sufficient postage under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C.

In the event that this Paper is late filed. and the necessary petition for extension of time is not filed concurrently herewith. please consider this as a Petition for the requisite extension of time, and to the extent not tendered by check attached hereto, authorization to charge the extension fee, or any other fee required in connection with this Paper to Account No. 06-1378.

SIR:

The present application is a CIP of International Application No. PCT/JP00/04902.

Submitted concomitantly herewith are the following:

- (1) Forms PTO/SB/08A and PTO/SB/08B;
- (2) A copy of the International Search Report for PCT/JP00/04902;
- (3) Copies of the publications cited in said International Search Report (WO 98/39352 and Tett. Letters, 40, 6465-6468 (1999));
- (4) Copies of other publications which are cited on said Forms PTO/SB/08A and PTO/SB/08B; and
- (5) A copy of copending related application Serial No. 09/925,673, filed August 9, 2001.

WO 98/39352, which is listed in the International Search Report for PCT/JP00/04902 is also discussed on page 2 of the present specification.



14

The enclosed copy of the International Search Report is in English.

It is respectfully requested that the attached publications be considered and made "of record".

Respectfully submitted,

RECHUENTER HOURS

RICHARD S. BARTH REG. NO. 28,180

FRISHAUF, HOLTZ, GOODMAN, LANGER & CHICK, P.C. 767 THIRD AVENUE - 25TH FLOOR NEW YORK, NEW YORK 10017-2023 Tel. No. (212) 319-4900 Fax No. (212) 319-5101

RSB/ddf

Enclosures: (1) Forms PTO/SB/08A and PTO/SB/08B

- (2) Publications identified on said Forms PTO/SB/08A and PTO/SB/08B
- (3) A copy of International Search Report for PCT/JP00/04902, dated October 10, 2000
- (4) A copy of copending related application Serial No. 09/925,673, filed August 9, 2001

Attorney Docket: 01834CIP/HG

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Takeshi IMANISHI et al.

Serial No. : 10/054,300

9 2002 Filed : January 22, 2002

NOVEL BICYCLONUCLEOSIDE

ANALOGUES

Art Unit

Examiner

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

copending related application Serial No.

09/925,673, filed August 9, 2001; and

+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	U.S. Facelit and Itademan	K OILICE: U.S. DEPARTMENT OF COMMERCE
Substitute for Form 1449A/PTO	Application Number	10/054,300
	Filing Date	January 22, 2002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT E	First Named Inventor	Takeshi IMANISHI
APR 1 9 2002	Group Art Unit	1646
	Examiner Name	
Sheet 1	Attorney Docket Number	01834CIP/HG

U.S. PATENT DOCUMENTS

Exam. Inits*	Cite No¹	Document Number	Kind Code²	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion
		09/925,673		KANEKO et al.		
		3,687,808		MERIGAN, Jr. et al.	08-29-1972	
		4,689,320		KAJI	08-25-1987	
		4,806,463		GOODCHILD et al.	02-21-1989	
		5,514,577		DRAPER et al.	05-07-1996	
		5,661,134		COOK et al.	08-26-1997	
		5,004,810		DRAPER	04-02-1991	
		5,166,195		ECKER	11-24-1992	
		5,194,428		AGRAWAL et al.	03-16-1993	
		5,242,906		PAGANO et al.	09-07-1993	
		5,248,670		DRAPER et al.	09-28-1993	
		5,442,049		ANDERSON et al.	08-15-1995	
		5,457,189		CROOKE et al.	10-10-1995	
		5,514,577		DRAPER et al.	05-07-1996	
		5,523,389		ECKER et al.	06-04-1996	
		5,580,767		COWSERT et al.	12-03-1996	
		5,582,972		LIMA et al.	12-10-1996	
		5,582,986		MONIA et al.	12-10-1996	
		5,591,600		ECKER	01-07-1997	
Examine Signatu			,	Date Considered		

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Place a check here if English translation is attached.

	oror racene and rracen	GIR CITICS. C.B. DEPARTMENT OF COMMERCE
Substitute for Form 1449A/PTO	Application Number	10/054,300
	Filing Date	January 22, 2002
INFORMATION DISCLOSURE OF E	First Named Inventor	Takeshi IMANISHI
APR 1 9 2002	Group Art Unit	1646
	Examiner Name	
Sheet 2	Attorney Docket Number	01834CIP/HG

U.S. PATENT DOCUMENTS

Exam. Inits*	Cite No¹	Document Number	Kind Code²	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion
		5,591,623		BENNETT et al.	01-07-1997	
		5,591,720		ANDERSON et al.	01-07-1997	
		5,607,923		COOK et al.	03-04-1997	
		5,620,963		COOK et al.	04-15-1997	
		5,658,891	:	DRAPER et al.	08-19-1997	
		5,661,134		COOK et al.	08-26-1997	
		5,681,747		BOGGS et al.	10-28-1997	
		5,681,944		CROOKE et al.	10-28-1997	
		5,691,461		ECKER et al.	11-25-1997	
		5,877,309		McKAY et al.	03-02-1999	
		5,955,443		BENNETT et al.	09-21-1999	
	ŀ	5,985,558		DEAN et al.	11-16-1999	
		6,111,094		BENNETT et al.	08-29-2000	
		6,127,533		COOK et al.	10-03-2000	

FOREIGN PATENT DOCUMENTS

Exam Inits'	Cite No¹	Offc³	Document Number	Kind Code ⁵	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	T
		WIPO	WO 94/08003		MONIA et al.	04-14-1994		
		WIPO	WO 96/31557		JACOBSEN	10-10-1996	10-10-1996	
		WIPO	WO 98/39352		IMANISHI	09-11-1998		
Examin Signat					Date Considered	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		. •

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPBP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Place a check here if English translation is attached.

	-	<u> </u>				
Substitute for Form 1449A/PTO		Application Number	10/054,300			
		Filing Date	January 22, 2002			
INFORMATION DESTATEMENT BY A	APPLICANT PE	First Named Inventor	Takeshi IMANISHI			
APR 1 9 2002		Group Art Unit 1646				
		Examiner Name				
Sheet 3	OF TIBE	Attorney Docket Number	01834CIP/HG			
	OTHER PRIOR ART	- NON-PATENT LITERATO	URE DOCUMENTS			
Examiner Cite Initials No. 1		(in CAPITAL LETTERS), title of e number(s), publisher, city and				
	Expression Precedes Derm	"Keratinocyte Intercellular Ad al T Lymphocytic Infiltration i J. Pathology, 1989, 135, 1045-1	n Allergic Contact Dermatitis			
		ence-Specific Recognition and M , Angew. Chem. Int. Ed. Engl.,				
		mically Modified Oligonucleotid national Edition, 1991, 30, 613				
		cal Modifications to Improve Up es", <u>Ann. N.Y. Acad. Sci.</u> , 1992				
		, "Tumor Cell Interactions with stasis", <u>Annu. Rev. Cell Biol.</u> ,				
	COOK, "Medicinal chemist Cancer Drug Design, 1991		s- future opportunities", <u>Anti-</u>			
		ction of <i>mdr1</i> Gene Amplification moted by Triple Helix-Forming Opment, 1999, 9, 261-270.				
	SANGHVI, "Heterocyclic Base Modifications in Nucleic Acids and their Applications in Antisense Oligonucleotides", Antisense Research and Applications, Ed. S.T. Crooke and B. Lebleu, CRC Press, 1993, 273-288 (Chapter 15).					
	SHIOHARA et al., "Fixed	Drug Eruption", <u>Arch. Dermatol.</u>	, 1989, 125, 1371-1412.			
Examiner Signature		Date Considered				

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Place a check here if English translation is attached.

			·	
Substitu	ıte fo	r Form 1449A/PTO	Application Number	10/054,300
		ŕ	Filing Date	January 22, 2002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT PE			First Named Inventor	Takeshi IMANISHI
APR 1 9 2002		App 1 9 2002	Group Art Unit	1646
	Armia		Examiner Name	
Sheet	4	of To	Attorney Docket Number	01834CIP/HG
		OTHER PRIOR ART	- NON-PATENT LITERATU	JRE DOCUMENTS
Examiner Initials ¹	Cite No.1		(in CAPITAL LETTERS), title of e number(s), publisher, city and	
		EBBINGHAUS et al., "Inhi Sequence by Triplex-Dire Biochemistry, 1999, 38,	bition of Transcription Elongat cted Covalent Modification of t 619-628.	ion in the HER-2/neu Coding he Template Strand",
			tion of Gene Expression and Celotides Directed to the <i>c-myc</i> Gen	
			leishmanicidal effect of phosp -mediated delivery", <u>Biochimica</u>	
			bition of HIV proliferation in a ed to lipophilic groups", <u>Bioch</u>	<u>-</u>
			duction of a lipophilic thioeth isense applications", <u>Bioorgani</u> 770.	
			c Acid-Oligonucleotide Conjugaton Company Letters, 1994, 4, 1053	es for Antisense Applications", -1060.
		YU et al., "Specific Inh to 3' Exonuclease-Defici	ibition of PCR by Non-Extendable ent DNA Polymerase", <u>Biotechniq</u>	e Oligonucleotides Using a 5' ues, 1997, 23, 714-720.
			ular adhesion molecule-I (ICAM- Dermatol., 1989, 120, 479-484.	I) expression correlated to
		TAM and FRASER-REID, "A 1979, 57, 2818-2822.	synthetic route to 4-C-methyl- x	ylo-furanose", <u>Can. J. Chem.</u> ,
Examiner Signature	•		Date Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 $^{^{1}}$ Unique citation designation number. 2 Place a check here if English translation is attached.

Substitute fo	r Form 144	9A/PTO	Application	on Number	10/054,300		
		,	Filing Dat	te	January 22, 2002		
	INFORMATION DISCLOSURE STATEMENT #Y APPLICANT			ed Inventor	Takeshi IMANISHI	_	
APR 1 9 2002		Group Art	Unit	1646			
		Examiner 1	Name				
Sheet	of	10	Attorney I	Docket Number	01834CIP/HG		
	OTHER P	RIOR ART	- NON-PAT	TENT LITERAT	URE DOCUMENTS		
Examiner Cite Initials No. 1					article, title of item, date, d/or country where published	T²	
		e growth fact			mor growth by expression of Cancer Immunol. Immunother.,		
		"Prospects fo <u>on</u> , 1996, 14(utic Use of Antige	ene Oligonucleotides", <u>Cancer</u>		
	like Growth	Factor-1 (IG	F-1) Receptor		Antisense RNA to the Insulin- c and Induce Regression of		
		Plasmid to th			genesis by an Antisense Receptor", <u>Cancer Research</u> ,		
					se 9 Expression by a Ribozyme <u>r Research</u> , 1996, 56, 5279-		
:	BRIMACOMBE (and CHING, "N e Research, 1	ucleophilic D 968, 8, 82-88	isplacement Reacti	ons in Carbohydrates",		
	selectin, P	BOGGEMEYER et al., "Borrelia Burgdorferi Upregulates the Adhesion Molecules E-selectin, P-selectin, ICAM-1 and VCAM-1 on Mouse Endothelioma Cells in vitro", Cell Adhesion and Communication, 1994, 2, 145-157.					
		KERR et al., "TGF- β 1 Inhibition of Transin/Stromelysin Gene Expression is Mediated through a Fos Binding Sequence", <u>Cell</u> , 1990, 61, 267-278.					
			ed nucleic ac <u>un.</u> , 1998, 4,		d high-affinity nucleic acid		
Examiner Signature				Date Considered			

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Place a check here if English translation is attached.

Substitute f	or Form 1449A/PTO	Application	on Number	10/054,300	
	·	Filing Dat	ce	January 22, 2002	
INFORMATION STATEMENT BY		First Name	ed Inventor	Takeshi IMANISHI	
	2002	Group Art	Unit	1646	
	APR 1 9 2002	Examiner 1	Name		
Sheet 6	Mr. 10	Attorney I	Docket Number	01834CIP/HG	
	OTHER PRIOR ART	- NON-PAT	ENT LITERAT	URE DOCUMENTS	
Examiner Cite Initials No. 1	Include name of autho page(s), volume-iss	r (in CAPITAL I ue number(s), p	LETTERS), title of publisher, city an	article, title of item, date, d/or country where published	T²
	BIRKENDAL-HANSEN, "Prot Cell Biology, 1995, 7,		ling of extracellu	lar matrix", <u>Current Opinion in</u>	
	LEROITH et al., "Molecu Receptor", <u>Endocrine Re</u>		_	Insulin-Like Growth Factor I	
		effectively in	hibit influenza vi	ligonucleotides combined with a rus reproduction and synthesis 1990, 259, 327-330.	
	PIERRE MARTIN, "Ein Zug Oligonucleotide", <u>Helv.</u>	_	-	und Eigenschaften deren	
	DELISSER et al., "Molec 1994, 15, 490-495.	ular and funct	ional aspects of P	ECAM-1/CD31", <u>Immunology Today</u> ,	
	HURTENBACH et al., "Pre Tissue Destruction is S Immunopharmac., 1996, 1	cid Mice Infect	=	rthritis, and Inflammatory Burgdorferi" <u>, Int. J.</u>	
	HIMELSTEIN et al., "Met MMP-9", <u>Invasion Metast</u>			sion: The Contribution of	
	HO et al., "Treatment o <u>Dermatol.</u> , 1990, 22, 64		n planus with cycl	osporine", <u>J. Am. Acad.</u>	
	activated Protein Kinas	e Kinase 1-inde cluding Closel	ependent and Requi	r Activity by ras Is Mitogeres Multiple Transcription and AP-1 Sequences", <u>J. Biol.</u>	
Examiner Signature			Date Considered		

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 $^{^1}$ Unique citation designation number. 2 Place a check here if English translation is attached.

+ PTO/SB/08B (08-00)
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO		Application	on Number	10/054,300					
				Filing Dat	te	January 22, 2002			
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			First Name	ed Inventor	Takeshi IMANISHI	_		
	APR 1 9 2002		Group Art	Unit	1646				
			Examiner 1	Name					
Sheet	7	To The Land	10	Attorney I	Docket Number	01834CIP/HG			
			RIOR ART	- NON-PAT	TENT LITERAT	URE DOCUMENTS			
Examiner Initials ¹	Cite No.1					article, title of item, date, d/or country where published	T ²		
		Regulated b	LITWIN et al., "Novel Cytokine-independent Induction of Endothelial Adhesion Molecules Regulated by Platelet/Endothelial Cell Adhesion Molecule (CD31)", <u>J. Cell Biol.</u> , 1997, 139, 219-228.						
		NEWMAN, "Th	e Biology of	PECAM-1", <u>J. (</u>	Clin. Invest., 199	7, 99, 3-8.			
		HAKUGAWA et al., "The Inhibitory Effect of Anti-Adhesion Molecule Antibodies on Eosinophil Infiltration in Cutaneous Late Phase Response in Balb/c Mice Sensitized with Ovalbumin (OVA)", <u>J. Dermatol.</u> , 1997, 24, 73-79. OUWERKERK-MAHADEVAN et al., "Isoenzyme-Selective Inhibition of Glutathione Conjugation in Vivo: Selective Inhibition of the Conjugation of S-2-Bromoisovalerylurea in the Rat", <u>J. Pharmacol. Exp. Therapeut.</u> , 1996, 276, 923-928.							
		protect cor		from excitote	-	NMDA-R1 receptor channel ocalischaemic infarctions",			
					ation of VNTR locu 1995, 23, 3050-305	s D1S80 using peptide nucleic 5.			
			, "Synthesis <u>rch</u> , 1995, 23	,	ribonucleotide N3'	→P5' phosphoramidates", <u>Nucleic</u>			
						ntiviral activity of lipid- <u>h</u> , 1990, 18, 3777-3783.			
		into liposo	mes and enhan	ced cell asso	orporation of 2'-O ciation through mo rch, 1992, 20, 533				
Examiner Signature					Date Considered				
		-			·				

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 $^{^{1}}$ Unique citation designation number. 2 Place a check here if English translation is attached.

| + |

Substitut	te fo	r Form 144	9A/PTO	Application	on Number	10/054,300	
			•	Filing Dat	ce	January 22, 2002	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT APR 1 9 2002			First Name	ed Inventor	Takeshi IMANISHI		
			Group Art	Unit	1646		
	; Arn			Examiner 1	Name		
Sheet	8	Of Of	10	Attorney I	Docket Number	01834CIP/HG	
		OTHER P	RIOR ART	- NON-PAT	ENT LITERAT	URE DOCUMENTS	
Examiner Initials ¹	Cite No.1					article, title of item, date, d/or country where published	T²
				"Novel 4'-Bra	anched Nucleosides	", <u>Nucleosides & Nucleotides</u> ,	
		MANOHARAN et al., "Oligonucleotide conjugates: alteration of the pharmacokinetic properties of antisense agents", Nucleosides & Nucleotides, 1995, 14, 969-973. REGEZI et al., "Vascular adhesion molecules in oral lichen planus", Oral Surg. Oral Med. Oral Pathol., 1996, 81, 682-690. HEGEMANN and MAHRLE, "Biochemical Pharmacology of Protein Kinase C and its Relevance for Dermatology", Pharmacology of the Skin, Ed. H. Mukhtar, CRC Press, Boca Raton, FL., 1992, 357-368. BERNHARD et al., "Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells", Proc. Natl. Acad. Sci., 1994, 91, 4293-4297.					
		sodium chans Acad. Sci., DEAN and MCI administrat:	nels, PN3/SNS 1999, 96, 76 KAY, "Inhibit	and NaN/SNS2 40-7644. ion of protein orothioate an	, in rat models of n kinase C-α expre	the tetrodotoxin-insensitive chronic pain", <u>Proc. Natl.</u> ession in mice after systemic mucleotides", <u>Proc. Natl. Acad.</u>	
RININSLAND et al., "Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells", Proc. Natl. Acad. Sci. , 1997, 94, 5854-5859. LETSINGER et al., "Cholesterol-conjugated oligonucleotides: Synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture", Proc. Natl. Acad. Sci. , 1989, 86, 6553-6556.							
Examiner Signature					Date Considered		

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Place a check here if English translation is attached.

				U.S. Patent and Trademar	k Office: U.S. DEPARTMENT OF COM	MERCE
Substitu	te fo	r Form 144	9A/PTO	Application Number	10/054,300	
			21., 2 20	Filing Date	January 22, 2002	
	_	ISCLOSURE APPLICANT		First Named Inventor	Takeshi IMANISHI	
/	∕o,,	2002		Group Art Unit	1646	-
\	APR '	/ A Mar		Examiner Name		***
Sheet	FAVT	of	10	Attorney Docket Number	01834CIP/HG	
		OTHER P	RIOR ART	- NON-PATENT LITERATU	RE DOCUMENTS	
Examiner Initials ¹	Cite No.1			(in CAPITAL LETTERS), title of e number(s), publisher, city and	· · · · · · · · · · · · · · · · · · ·	T^2
				riple-helix formation by oligonu and guanine", <u>Proc. Natl. Acad.</u>		
				ogy of Disease: Insulin-Like Gro , 1995, 73, 311-331.	owth Factor-I Receptor",	
		MILNER, "Cha	arles Darwin	and Associates, Ghostbusters", \underline{S}	Ccientific American, 1996, 275,	
		BYNE, "The l	Biological Ev	idence Challenged", <u>Scientific A</u>	<u>umerican</u> , May 1994, 50-55.	
				lation of Anxiety and Neuropepti <u>Science</u> , 1993, 259, 528-531.	de Y-Y1 Receptors by Antisense	
KOSHKIN et al., "LNA (Locked Nucleic Acids): Synthesis of the Adenine, Cytosine, Guanine, 5-Methylcytosine, Thymine and Uracil Bicyclonucleoside Monomers, Oligomerisation, and Unprecedented Nucleic Acid Recognition", Tetrahedron, 1998, 54 3607-3630.						
			•	cleoside Phosphoramidite Synthon <u>Asymmetry</u> , 1995, 6, 1051-1054.	Derived from 1R,2S-	
		MANOHARAN e	t al., "Lipid	ic Nucleic Acids", <u>Tetrahedron L</u>	<u>etters</u> , 1995, 36, 3651-3654.	

Date

Considered

DATE MAILED: April 19, 2002

Examiner

Signature

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 $^{^{1}}$ Unique citation designation number. 2 Place a check here if English translation is attached.

	· · · · · · · · · · · · · · · · · · ·			
Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT APR 1 9 2002		Application Number	10/054,300	
		Filing Date	January 22, 2002	
		First Named Inventor	Takeshi IMANISHI	
		Group Art Unit		
		Examiner Name		
Sheet 10	of 10	Attorney Docket Number	01834CIP/HG	
OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS				
Examiner Cite Initials No. 1	Include name of author page(s), volume-issu	(in CAPITAL LETTERS), title of e number(s), publisher, city ar	article, title of item, date, ad/or country where published	T ²
		-type conformation, $2'-0,4'-C-m$	e duplexes containing nucleoside methylenerionucleosides",	
	OBIKA et al., "Synthesis of a conformationally locked AZT analogue, 3'-azido-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine", <u>Tetrahedron Letters</u> , 1999, 40, 6465-6468.			
	BERKOW et al., eds, The Merck Manual of Diagnosis and Therapy, 15th Ed., Rahway, NJ, 1987, 2263-2277.			
	BERKOW et al., eds, The Merck Manual of Diagnosis and Therapy, 15th Ed., Rahway, NJ, 1987, 2283-2285.			
	BERKOW et al., eds, The Merck Manual of Diagnosis and Therapy, 15th Ed., Rahway, NJ, 1987, 2286-2292.			
	BERKOW et al., eds, The Merck Manual of Diagnosis and Therapy, 15th Ed., Rahway, NJ, 1987, 2301-2310.			
	ALBERT and MORRIS, "Antisense knockouts: molecular scalpels for the dissection of signal transduction", <u>Trends in Pharmacological Sciences</u> , 1994, 15, 250-254.			
Examiner Signature		Date Considered		

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 $^{^{1}}$ Unique citation designation number. 2 Place a check here if English translation is attached.